Paper Details

  1. Home
  2. Paper Details

Withdrawal of anticancer therapy in advanced disease: a systematic literature review.

Author: BarclayS, ClarkeG, CorrieP, JohnstonS, KuhnI

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

This research examines the challenges of stopping anticancer treatments as the end of life approaches. The study explores the differences between conventional cytotoxic agents and newer molecular targeted agents (MTAs), particularly small molecule kinase-inhibitors (KIs), in terms of toxicity, effectiveness, and cost. The study highlights the need for clear guidelines on stopping treatment at the end of life.
Paper Details　
Original Abstract of the Article :
Current guidelines set out when to start anticancer treatments, but not when to stop as the end of life approaches. Conventional cytotoxic agents are administered intravenously and have major life-threatening toxicities. Newer drugs include molecular targeted agents (MTAs), in particular, small mole...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641339/

データ提供：米国国立医学図書館（NLM）

Navigating the End of Life: When to Stop Anticancer Therapy

The desert of advanced disease can be a challenging landscape to navigate, particularly when it comes to deciding when to stop anticancer therapy. This study, like a seasoned explorer offering guidance through uncharted territory, explores the complexities of withdrawing anticancer therapy in the context of end-of-life care. The authors delve into the ethical and practical considerations surrounding this sensitive topic, particularly in the context of newer molecular targeted agents (MTAs).

A Challenging Decision: When to Stop Treatment

The study highlights the need for clear guidelines on when to stop anticancer therapy, particularly as newer agents, like MTAs, offer extended survival benefits but are also more expensive. This dilemma, like a crossroads in the desert, presents a complex decision for both patients and clinicians.

Guiding Principles for End-of-Life Care

This study, like a beacon of light in the desert, emphasizes the importance of open communication and shared decision-making between patients and clinicians in the context of end-of-life care. The authors call for a nuanced approach to withdrawing anticancer therapy, taking into account individual patient preferences, the potential benefits and risks of continued treatment, and the financial implications. This comprehensive framework, like a well-stocked caravan, can help navigate the challenging terrain of end-of-life decisions.

Dr.Camel's Conclusion

This study provides valuable insights into the ethical and practical considerations surrounding the withdrawal of anticancer therapy in the context of advanced disease. The authors emphasize the importance of clear guidelines and a personalized approach, recognizing the complex interplay of medical, ethical, and financial factors. As we continue to explore the vast desert of end-of-life care, this study serves as a vital guidepost, offering a compassionate and informed approach to navigating this challenging terrain.

Date :
  1. Date Completed 2016-08-19
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

26559912

DOI: Digital Object Identifier

PMC4641339

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.